This forum is for questions about medical issues and research aspects of
Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new
Hepatitis Social/Living with Hepatitis forum
To me Blue Shield is managed in a very capitalist and efficient way. It has nothing to do with communism. Why insure sick people? It just cost money. So yes, they artificially introduce some bureaucratic elements to discourage more people but that's just an illusion of inefficiency. I bet they send the same letter to everyone. Even if a few percents of the people give up, it translate into millions of $ saved every year.
Good luck!
Good luck
Bobby
Call either (which ever is appropriate):
Pegassist (Roche Pegasys system): 1-877-734-2797
Commitment to Care (Schering- Plough PEG-Intron system): 1-800-521-7157
and ask to speak to a counselor regarding your situation. You may qualify for no cost HCV meds shipped to your home or office hassle free. I’ve received almost two years of free meds, no co-pays required from Commitment to Care. The people there rock, and the approval process moves quickly; it can take as little as a few days.
Good luck to you—
Bill
Check was in mail next day. Maybe that could help your situation.
Good luck.
I had to call/write the Public Regulations Commission re: my insurance lapsing, now the commission has asked me to send all my bills so they can monitor and make sure the insurance company is paying for everything they should.
I call the insurance co. whenever I dont understand what the heck they are talking about, one time they didn't cover a visit and I called and they said they would bring it up at some meeting to re'evaluate. I think I'll make my copies and let the PRC monitor them....
I dont know if the PRC in your area would be of any help. They investigate insurance companies... I even had some one from BCBS call me and say they received the PRC complaint and they are reinstating my insurance w/o any lapse time.. no wonder the health care system is so screwed up with all this paper work and business people making medical decisions. Gawd help us.
Evolving Therapeutic Arsenal for Hepc. In a nut shell
New Directions in Hepatitis C Therapy: A Look at the Evolving Therapeutic Arsenal
Posted 09/05/2008
Zobair M. Younossi, MD, MPH, FACP, FACG
Author Information
Introduction
Chronic hepatitis C continues to be the most important cause of chronic liver disease in the United States, potentially resulting in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. The only US Food and Drug Administration-approved treatment for hepatitis C is combination therapy with pegylated interferon alfa and ribavirin (standard of care), which leads to a sustained virologic response (SVR) in approximately 80% of patients infected with hepatitis C virus (HCV) genotype 2, approximately 60% to 65% infected with genotype 3, and approximately 40% of patients infected with HCV genotype 1.[1-3] If SVR is achieved, durable response is quite likely, providing patients with an excellent chance for long-term viral eradication.
In addition to a relatively low SVR rate in HCV genotype 1 patients, other challenges associated with the current anti-HCV treatment regimen are its side effects and the required duration of therapy, both of which interfere with patients' adherence to the full course of antiviral therapy. In fact, recent reports suggest that the inability to maintain the optimal dose of both pegylated interferon alfa and ribavirin, especially early in the course of treatment, is associated with a lower rate of response to the current standard of care therapy.[3] This may explain, in part, the difference between response rates reported in randomized clinical trials (indicating the efficacy of treatment) compared with the response rates reported in clinical practices (indicating the effectiveness of treatment). To overcome these challenges, recent investigations have focused on optimal management of treatment-associated side effects such as anemia and depression.[1-3]
In addition to managing side effects, research has also focused on developing models to predict low response probability in an effort to avoid futile treatment, and high response probability in an effort to support a full regimen for patients likely to achieve viral eradication. These predictive models are based on viral kinetic data at weeks 4, 12, and 24. Patients who achieve rapid virologic response (RVR; undetectable HCV RNA [< 10 IU/mL] by polymerase chain reaction [PCR] after 4 weeks of treatment) have an excellent chance of achieving SVR.[1,2] In contrast, failure to achieve an early virologic response by week 12 of treatment (a minimum of 2-log drop in HCV RNA from the baseline value) is a reliable negative predictor of response to this combination therapy regimen.[1,2] Furthermore, patients who continue to have detectable virus after 24 weeks of therapy are unlikely to achieve SVR and are considered "nonresponders" to combination therapy.
Although findings on viral kinetics and adherence can help clinicians individualize therapy and maximize SVR, many patients, especially those infected with HCV genotype 1, fail to respond to the current standard-of-care treatment. This has led to the development of new strategies and medications for HCV treatment. Although a number of approaches are under consideration, 3 strategies appear most promising: (1) improving the pharmacokinetics and side-effect profile of interferon; (2) improving the pharmacokinetics and side-effect profile of ribavirin; and (3) targeting viral enzymes required for HCV viral replication. This report discusses the most recent findings with regard to these new approaches to the treatment of HCV infection, with special focus on specifically targeted antiviral therapy for hepatitis C (STAT-C) regimens.[4,5]
1. At the time of the switch I was 58 weeks into a 72 week course of treatment. Blue Cross decided to cut my treatment off claiming there was no proof of efficacy beyond 48 week. My local GI and my GI at Shands had to get involved in the appeal. It took over a month, thank goodness Roche stepped in and helped me out for a month. Oh get this, they would approve the Riba but not the Peg.
2. They tried to cut off my Aranesp/Procrit saying my PCP said it wasn't medically necessary. At the time this happened my PCP wasn't even in the country. The truth was they cut my off because my labs showed a normal hgb. Uhhh... Duhhh... it was normal because I had been taking Aranesp.
3. My husband had surgery for sleep apnea in May. Not only did the doctor call ahead of time to confirm benefits, so did my husband. My husband even confirmed what each co pay for each provider would be (i.e., surgical center, anesthesiologist, pathology, doctor, lab). Blue Cross paid the surgical center, the anesthesiologis, the patholoy and the lab. When itcame time to pay the doctor, they dediced to put the claim under review to see if the procedure was medically necessary. This is August, the doctor has still not been paid.
4. Shands has not recommended that I do something called suppresive therapy. It's similar to the maintenance that failed (Halt-C) except it included Riba. As expected it has been denied by Blue Cross. Dr. Nelson at Shands already talked to Blue Cross' medical director who doesn't have a clue. The claim has now been sent out for independent medical review.
Needless to say I am not a fan of Blue Cross at all. (Note this is Blue Cross of Florida, Health Options PPO). I have an endoscopy and colonoscopy coming up on Tuesday. I fully expect Blue Cross to give me a hard time over these procedures.
Expect to fight every single claim that is submitted to them, expect to play the telephone shuffle came and make sure you get EVERYTHING well documented and whenever possible ask them "can you send me that in an email please".
Mouse
P.S. Do ya think this thread hit a nerve with me LOL